# Entasis Therapeutics Holdings Inc.

Entasis Therapeutics Holdings Inc. is a company headquartered in Waltham, MA, United States.

## Company overview

- **Legal name:** Entasis Therapeutics Holdings Inc.
- **Former names in filing history:** Entasis Therapeutics Ltd (2017-12-08 to 2018-08-17)
- **Classification:** Company
- **Industry (SIC):** 2834 — Pharmaceutical Preparations
- **Headquarters:** Waltham, MA, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0001724344

## About

Entasis Therapeutics Holdings Inc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001724344, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2022-03-03, it reported net income of USD -47,141,000; total assets of USD 40,920,000 for the fiscal period ended 2021-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2021 (period ended 2021-12-31)

- **Net income:** -$47.1M (USD -47,141,000)
- **Total assets:** $40.9M (USD 40,920,000)
- **Cash and equivalents:** $32.3M (USD 32,307,000)
- **Operating cash flow:** -$43.0M (USD -42,972,000)

### FY2020 (period ended 2020-12-31)

- **Net income:** -$50.5M (USD -50,496,000)
- **Total assets:** $61.6M (USD 61,558,000)
- **Cash and equivalents:** $53.2M (USD 53,247,000)
- **Operating cash flow:** -$45.4M (USD -45,426,000)

### FY2019 (period ended 2019-12-31)

- **Revenue:** $7.0M (USD 7,000,000)
- **Net income:** -$43.9M (USD -43,850,000)
- **Total assets:** $51.0M (USD 51,034,000)
- **Cash and equivalents:** $16.0M (USD 16,034,000)
- **Operating cash flow:** -$44.7M (USD -44,743,000)

### FY2018 (period ended 2018-12-31)

- **Revenue:** $5.0M (USD 5,000,000)
- **Net income:** -$33.0M (USD -32,952,000)
- **Total assets:** $89.3M (USD 89,274,000)
- **Cash and equivalents:** $49.4M (USD 49,360,000)
- **Operating cash flow:** -$35.8M (USD -35,817,000)

## Recent SEC filings

- Form 8-K — filed 2022-07-11 — period 2022-07-07 — FORM 8-K
- Form 8-K — filed 2022-05-23 — period 2022-05-23 — FORM 8-K
- Form 10-K/A — filed 2022-05-02 — period 2021-12-31 — 10-K/A
- Form 10-Q — filed 2022-04-27 — period 2022-03-31 — 10-Q
- Form 8-K — filed 2022-04-27 — period 2022-04-27 — 8-K
- Form 10-K — filed 2022-03-03 — period 2021-12-31 — 10-K
- Form 8-K — filed 2022-03-03 — period 2022-03-03 — 8-K
- Form 8-K — filed 2022-02-25 — period 2022-02-24 — FORM 8-K
- Form 8-K — filed 2022-02-18 — period 2022-02-17 — FORM 8-K
- Form 8-K — filed 2022-01-14 — period 2022-01-10 — FORM 8-K
- Form 8-K — filed 2021-11-12 — period 2021-11-10 — FORM 8-K
- Form 10-Q — filed 2021-11-04 — period 2021-09-30 — 10-Q

---

Updated: 2026-10-23T20:12:17Z

Canonical page: https://altss.com/profile/entasis-therapeutics-holdings-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology